HomeCompareABBV vs MCO

ABBV vs MCO: Dividend Comparison 2026

ABBV yields 3.12% · MCO yields 0.89%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MCO wins by $102.5K in total portfolio value· pulled ahead in Year 9
10 years
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →
MCO
MCO
● Live price
0.89%
Share price
$432.05
Annual div
$3.85
5Y div CAGR
74.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$207.2K
Annual income
$113,279.94
Full MCO calculator →

Portfolio growth — ABBV vs MCO

📍 MCO pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABBVMCO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABBV + MCO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABBV pays
MCO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
MCO
Annual income on $10K today (after 15% tax)
$75.74/yr
After 10yr DRIP, annual income (after tax)
$96,287.95/yr
At 15% tax rate, MCO beats the other by $74,421.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABBV + MCO for your $10,000?

ABBV: 50%MCO: 50%
100% MCO50/50100% ABBV
Portfolio after 10yr
$155.9K
Annual income
$69,502.83/yr
Blended yield
44.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
MCO
Analyst Ratings
18
Buy
13
Hold
1
Sell
Consensus: Buy
Price Target
$543.08
+25.7% upside vs current
Range: $480.00 — $620.00
Altman Z
5.3
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABBV buys
7
MCO buys
0
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABBVMCO
Forward yield3.12%0.89%
Annual dividend / share$6.65$3.85
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.6%74.8%
Portfolio after 10y$104.7K$207.2K
Annual income after 10y$25,725.73$113,279.94
Total dividends collected$63.0K$178.5K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$256.15$543.08

Year-by-year: ABBV vs MCO ($10,000, DRIP)

YearABBV PortfolioABBV Income/yrMCO PortfolioMCO Income/yrGap
1$11,559$438.51$10,856$155.76+$703.00ABBV
2$13,494$640.86$11,892$276.24+$1.6KABBV
3$15,951$945.97$13,219$494.35+$2.7KABBV
4$19,152$1,413.89$15,042$897.70+$4.1KABBV
5$23,443$2,146.38$17,763$1,668.77+$5.7KABBV
6$29,391$3,321.96$22,226$3,219.45+$7.2KABBV
7$37,948$5,265.87$30,363$6,580.83+$7.6KABBV
8$50,795$8,596.74$47,175$14,686.41+$3.6KABBV
9← crossover$71,034$14,549.41$87,754$37,276.83$16.7KMCO
10$104,715$25,725.73$207,177$113,279.94$102.5KMCO

ABBV vs MCO: Complete Analysis 2026

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →

MCOFinancials

Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations, as well as and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers offshore analytical and research services with learning solutions and certification programs; and software solutions, as well as related risk management services. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.

Full MCO Calculator →
📬

Get this ABBV vs MCO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABBV vs JNJABBV vs MRKABBV vs PFEABBV vs BMYABBV vs LLYABBV vs SCHDABBV vs JEPIABBV vs O

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.